Blocking beta-amyloid pathway prevented chronic pain in mice

A hind-paw injection designed to mimic tissue injury gave researchers at the University of California, Irvine, a view of the moment pain can change course. Days after the injury, blocking a beta-amyloid pathway in the spinal cord prevented the mice from developing chronic pain, while their initial response to injury remained intact. Daniele Piomelli, distinguished professor of anatomy and neurobiology, led the study published in Science Translational Medicine.

Normally, oligodendrocytes—cells that maintain myelin, the fatty insulation around nerve fibers—help protect the structure of those fibers. After injury, they reduced the machinery needed to make myelin. Nearby nerve fibers then lost structural integrity, and neurons produced amyloid precursor proteins that generate beta-amyloid 42. The fragment rose in the spinal cord precisely as temporary pain shifted toward the lasting hypersensitivity used to represent chronic pain in the mice.

To separate cause from coincidence, Piomelli's team intervened in several ways. They studied genetically engineered mice lacking amyloid precursor protein, used an antibody to neutralize beta-amyloid, tested three chemically distinct drugs, and removed a gene needed for amyloid precursor protein production. In every case, intervening in the beta-amyloid pathway during the early window prevented lasting pain without erasing the acute response to injury. Mice lacking the upstream enzyme N-acylethanolamine acid amidase specifically in oligodendrocytes were also protected, including in a separate nerve-injury model.

Concretely, the finding points toward a change in timing rather than simply another painkiller. Nearly all current treatments target pain after it has become chronic; if the same pathway is confirmed in people, a future therapy might intervene during a brief post-injury window, while the process is still reversible. For patients today, however, the study offers no established treatment: the evidence comes from mice, and researchers still need to determine whether the pathway operates in humans and can be targeted safely.

The amyloid link also raises a second line of inquiry. Months after injury, the mice developed spinal deposits resembling Alzheimer's-related plaques, suggesting that chronic pain and neurodegenerative disease may share more biology than previously thought. That resemblance does not make Alzheimer's drugs pain treatments: Piomelli said existing Alzheimer's or amyloid-targeting medicines should not be used off-label for pain.